EU finds Johnson & Johnson COVID shot possibly linked to another rare clotting condition

Earlier some serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with J&J's vaccine from its Janssen unit

Agencies
Representative Image
The European Union's drug regulator said on Friday there is a possible link between rare cases of bloods clots in deep veins with Johnson & Johnson's COVID-19 vaccine and recommended the condition be listed as a side-effect of the shot.

The European Medicines Agency also recommended immune thrombocytopenia (ITP), a bleeding disorder caused by the body mistakenly attacking platelets, be added as an adverse reaction with an unknown frequency to the J&J vaccine product information and to AstraZeneca's vaccine.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › News › International › World News › EU finds Johnson & Johnson COVID shot possibly linked to another rare clotting condition
Text Size:AAA
Success
This article has been saved

*

+